The low expression of CD80 correlated with the vascular endothelial growth factor in esophageal cancer tissue

Yang, Wenyan; Zhang, Y.; Yu, Jinming; Li, S.

doi:10.1016/j.ejso.2010.01.007

Cited by 5 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast with the hypothesis of protective role of higher CD80 / CD86 gene expression, we also found that upregulated expression of CD86 associated with a greater tumor size (pT 3-4 ) and that nonmetastatic PTC (pN 0 ) had a reduced expression of CD80 compared to metastatic ones (pN 1 ). Indeed, these observations were also in contrast with the previously reported results on esophageal cancer, where the lower CD80 protein level was associated with the presence of lymph node metastasis [ 53 ]. Although these differences may be due to tumor-specific biology, they also highlight the necessity to corroborate our findings on larger case studies.…”

Section: Discussioncontrasting

confidence: 99%

“…In addition, a lower CD80 mRNA level was observed to associate with the more aggressive follicular PTC variant. These findings corroborate previous evidence showing reduced expression of CD80 in many cancer types (i.e., melanoma, myeloma, acute myeloid leukemia, bladder, and colon carcinoma) and are in agreement with the observation of its lower expression in poorer differentiated esophageal cancers, compared to well- and moderate-differentiated ones [ 21 , 52 , 53 ]. Thus, it may be tempting to speculate that reduced CD80 gene expression may confer an advantage to tumor growth.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

Tuccilli

Baldini

Sorrenti

et al. 2018

International Journal of Endocrinology

View full text Add to dashboard Cite

The dysregulation of PD-1 ligands (PD-L1 and PD-L2) and CTLA-4 ligands (CD80 and CD86) represents a tumor strategy to escape the immune surveillance. Here, the expression of PD-L1, PD-L2, CD80, and CD86 was evaluated at the mRNA level in 94 patients affected by papillary thyroid carcinoma (PTC) and 11 patients affected by anaplastic thyroid carcinoma (ATC). Variations in the mRNAs in PTC patients were then correlated with clinicopathological features. The expression of all genes was deregulated in PTC and ATC tissues compared to normal tissues. In particular, the downregulation of CD80 was observed above all in ATC. In addition, the increased expression of CD80 associated with longer disease-free survival in PTC. Higher expression of PD-L1 associated with the classical histological variant and with the presence of BRAFV600E mutation in PTC. The increased PD-L2 expression correlated with BRAFV600E mutation and lymph node metastasis, while its lower expression correlated with the follicular PTC variant. The latter was also associated with the CD80 downregulation, which was also related to the absence of lymph node metastasis. In conclusion, we documented the overall dysregulation of PD-1 and CTLA-4 ligands in PTC and ATC tissues and a possible prognostic value for CD80 gene expression in PTC.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 92%

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

Tuccilli

Baldini

Sorrenti

et al. 2018

International Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…It is reported that low expression of CD80 can be associated with VEGF overexpression. CD80 impairment in the ESCC tissues is correlated with poor survival, which indicates the dysfunction of the immune system and promotes the ESCC progression ( 123 ). Some studies have confirmed that VEGF-C, a lymphangiogenic factor, is associated with survival, tumor depth, stage, and lymph node metastasis of ESCC ( 124 , 125 ).…”

Section: The Role Of Cellular Communication In Esophageal Squamous Ce...mentioning

confidence: 99%

The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma

2022

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers in the world, with a high rate of morbidity. The invasion and metastasis of ESCC is the main reason for high mortality. More and more evidence suggests that metastasized cancer cells require cellular elements that contribute to ESCC tumor microenvironment (TME) formation. TME contains many immune cells and stromal components, which are critical to epithelial–mesenchymal transition, immune escape, angiogenesis/lymphangiogenesis, metastasis niche formation, and invasion/metastasis. In this review, we will focus on the mechanism of different microenvironment cellular elements in ESCC invasion and metastasis and discuss recent therapeutic attempts to restore the tumor-suppressing function of cells within the TME. It will represent the whole picture of TME in the metastasis and invasion process of ESCC.

show abstract

“… 12 In esophageal cancer, the expression of the co-stimulatory molecule CD80 is significantly down-regulated and inversely correlated with TGF-β1 and IL-10 expression. 13 , 14 Moreover, metastatic esophageal cancer cells are less sensitive to specific cytotoxic lymphocytes. 15 In addition, in these neoplasms, CD3+ and CD8+ tumor-infiltrating lymphocytes (TIL) show functional exhaustion and express high levels of PD-1.…”

Section: Introductionmentioning

confidence: 99%

Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response

et al. 2020

View full text Add to dashboard Cite

After neoadjuvant chemoradiotherapy for esophageal adenocarcinoma, up to 29% of patients have a pathological complete response (pCR). What to do afterward is still under debate. The aim of this prospective study was to define which local markers of immune response might act as predictors of pCR and of recurrence after pCR. The peritumoral healthy mucosa of the surgical specimen was sampled at esophagectomy and analyzed by immunohistochemistry, flow cytometry and Real-Time PCR. One hundred and twenty-three patients received neoadjuvant therapy for esophageal adenocarcinoma and were included in the study. Significantly higher rate of natural killer (NK) cells (CD57+), intraepithelial CD8 + T lymphocytes and degranulating T-and NK-cells (CD107+) were observed in the healthy mucosa of patients with pCR. Moreover, pCR was characterized by a lower immune-check points gene expression level. T-cell activation markers mRNA levels were significantly lower in patients with pCR and recurrent disease, showing an excellent accuracy in the prediction of the postoperative recurrence. Costimulatory molecules mRNA relative levels tended to be lower in patients with pCR and recurrent disease, showing a good accuracy in the prediction of postoperative recurrence in patients with pCR. The immune profile identified in this study might further be tested in large prospective trials as marker of pCR after neoadjuvant therapy and as predictor of recurrence after pCR.

show abstract

The low expression of CD80 correlated with the vascular endothelial growth factor in esophageal cancer tissue

Cited by 5 publications

References 23 publications

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid Cancers

The Role of Tumor Microenvironment in Invasion and Metastasis of Esophageal Squamous Cell Carcinoma

Immune surveillance activation after neoadjuvant therapy for esophageal adenocarcinoma and complete response

Contact Info

Product

Resources

About